Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SpringWorks Therapeutics, Inc.

Market Cap 3.54B 3.06B 2.82B 2.64B 4.94B 337B 5.02B 33.27B 12.97B 164B 13.29B 13.01B 567B P/E Ratio 2023
-7.09x
P/E Ratio 2024 -10.4x
Enterprise Value 3.09B 2.67B 2.46B 2.3B 4.31B 293B 4.38B 29.01B 11.31B 143B 11.58B 11.34B 494B EV / Sales 2023
362,507,725x
EV / Sales 2024 11,654,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
1 year 46.74
Extreme 46.735
47.02
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap.
01/07/25Issuer sale

Director

103,482 0.1381%
01/07/25Issuer sale

Executive/Senior Manager

379,322 0.5062%
01/07/25Issuer sale

Chief Operating Officer

895,788 1.1954%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%+0.51%+72.44% 3.54B
+0.23%-3.33%+17.72%-18.53% 62.21B
+1.44%+5.93%+66.81%+220.92% 59.45B
+0.70%+29.50%+29.50%+29.50% 38.9B
+0.26%+16.11%-55.36%-64.79% 36.4B
+0.16%+2.04%+50.65%-36.40% 29.52B
+0.73%+6.28%+57.19%+75.22% 21.54B
+0.72%+5.82%+83.55%-59.36% 19.7B
+4.80%+0.07%-4.38%+103.05% 16.18B
+0.18%-1.66%+49.80%+101.47% 15.89B
Average +0.82%+2.13%+29.60%+42.35% 30.33B
Weighted average by Cap. +0.72%+2.90%+30.66%+45.11%

Financials

2023 2024
Net sales 5.45 4.7 4.34 4.06 7.6 517.74 7.72 51.19 19.96 252 20.44 20.01 872.56 191.59 165.48 152.49 142.73 267.49 18.21K 271.63 1.8K 702 8.86K 719.03 703.73 30.69K
Net income -325M -281M -259M -242M -454M -30.9B -461M -3.06B -1.19B -15.04B -1.22B -1.19B -52.08B -258M -223M -205M -192M -360M -24.54B -366M -2.43B -946M -11.94B -969M -948M -41.35B
Net Debt -656M -566M -522M -488M -915M -62.31B -929M -6.16B -2.4B -30.33B -2.46B -2.41B -105B -454M -392M -361M -338M -634M -43.15B -644M -4.27B -1.66B -21B -1.7B -1.67B -72.73B
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!